Results about: cancer
Recent years have seen a paradigm shift in our understanding of gene activity and regulation. It is now clear that processing of primary transcripts as well as translational control open a myriad of opportunities for gene regulation, which are extensively used in virtually every human gene.
The Signalling and Cell Cycle Laboratory focuses on studying the basic mechanisms of cell regulation, especially regarding how external signals are interpreted by cells to modulate cell proliferation, differentiation and survival. Our research centers on two main subjects:
A high resolution description of the structure and dynamics of proteins is a very useful tool to study the properties and the function of these important biomacromolecules and, most importantly, to understand how changes in sequence or environment can lead to disease.
Candidates with a strong interest in the microtubule cytoskeleton who would like to join our group should e-mail a cover letter with CV including contact information for references to jens.ludersirbbarcelona.org.
Despite tremendous progress in therapeutic drug development, more than 80% of all human proteins remain beyond the reach of traditional drug discovery. Classical drug design mostly relies on synthetic compounds that block specific biochemical activities of proteins.
These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.
Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.
The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
Identification of a determining factor in luminal cancer cells, that cause the greatest number of breast cancer cases
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.